REHOVOT, Israel and BETHESDA, Md., Sep 29, 2022
CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the peer-reviewed publication of its sponsored preclinical study titled “The Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue” in the International Journal of Molecular Sciences; concluding “possible future therapeutic value” for the company’s proprietary drug candidate currently under development, PLP-33, for the treatment of colonic polyps.
Study design included collection of both polypoid tissue biopsies and healthy colonic tissue biopsies from 22 patients. A synergistic interaction of cannabinoid compounds against colonic polyps was observed, as well as a differential toxic effect between polypoid tissue and healthy colonic mucosa in some of the cases, thus “suggesting possible future therapeutic value”.
The present study was led by Gastroenterologists Dr. Dana Ben-Ami Shor (MD), and Dr. Erez Scapa (MD) of the Tel Aviv Sourasky Medical Center in Israel. The abstract and full text of the article titled “The Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue”, published on the International Journal of Molecular Sciences, can be accessed in the following link: https://www.mdpi.com/1422-0067/23/19/11366.
CNBX Pharmaceuticals is currently developing its proprietary Drug Candidate PLP-33 for the treatment of colonic polyps. This activity is conducted in collaboration with Digestix Bioscience Inc. (a CNBX Pharmaceuticals subsidiary).
About CNBX Pharmaceuticals:
CNBX Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cnbxpharma.com. For the latest updates on CNBX Pharmaceuticals, follow the Company on Twitter @cnbxpharma, Facebook @cnbxPharmaceuticals, LinkedIn, and Instagram @CNBX_Pharmaceuticals.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.